DRKS00016064已完成4 期
Evaluation of immunological effects of the RANKL-inhibitor Denosumab when administered concurrently with PD1-blocking antibodies (Nivolumab, Pembrolizumab) in patients with metastatic malignant melanoma with bone involvement - Bonemet
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Alcedis GmbH
- 入组人数
- 17
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Provision of tumor tissue from metastatic site of disease for biomarker analysis and confirmation of diagnosis by central laboratory. Tissue must be obtained before PD-1 inhibitor therapy (either baseline FFPE sample or archival tissue (ideally obtained after preceding medical tumor therapies).
- •Inoperable metastatic stage IV melanoma arising from a primary cutaneous site or metastatic from an unknown primary site or melanoma of mucosal or uveal origin.
- •Planned therapy with PD-1 blocking antibody (nivolumab or nivolumab + ipilimumab or pembrolizumab) and denosumab as standard of care.
- •Measurable disease according to RECIST1.1 and at least one documented bone metastasis.
- •Age 18 years or above.
- •Written, informed consent.
- •Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study
- •Minimum life expectancy of 6 months
- •ECOG performance status of 0-2
- •Screening laboratory values must meet the following criteria and should be obtained within 14 days prior to registration:
- •oWBC = 2000/µL
- •oNeutrophils = 1000/µL
- •oPlatelets = 100 x103/µL
- •oHemoglobin = 9.0 g/dL
- •oSerum creatinine = 2.0 x ULN OR
- •oCreatinine clearance (CrCl) = 35mL/min (using the Cockcroft-Gault formula)
- •oAST/ALT = 3 x ULN, in case of liver metastases = 5 x ULN
- •oTotal Bilirubin = 2.0 x ULN (except subjects with Gilbert Syndrome, who may have total bilirubin up to 5 x ULN)
- •oSerum calcium or albumin-adjusted serum calcium within normal limits
- •Prior radiotherapy must have been completed prior to study drug administration
- •Negative pregnancy test for female subjects within the week before treatment start and effective contraception for both male and female subjects if the risk of conception exists
排除标准
- •Prior therapy with CTLA-4-inhibitor or PD-1-inhibitor or denosumab for distant metastatic disease. Treatments in the adjuvant setting are allowed in case treatment was discontinued at least 4 weeks before inclusion in this study.
- •No other concurrent medical treatments for metastatic disease such as targeted therapies or chemotherapies are allowed. Treatments in the adjuvant setting are allowed in case treatment was discontinued at least 4 weeks before inclusion in this study.
- •Active CNS metastases requiring local therapy or steroid therapy
- •Use of any investigational or non-registered product (drug or vaccine) within the past 30 days before study start and during study
- •Psychiatric or addictive disorders of the patient that may compromise his/her ability to give informed consent or to comply with the trial procedures.
- •Significant dental/oral disease, including prior history or current evidence of osteonecrosis/osteomyelitis of the jaw, or the following: Active dental or jaw condition which requires oral surgery. Non-healed dental/oral surgery. Planned invasive dental procedures for the course of the study.
- •Relevant immune deficiencies or relevant autoimmune disease, as assessed by the investigator.
- •Other malignancies within the past three years which need treatment except basal or squamous skin carcinomas or carcinoma in situ of the cervix
- •Serious cardiac, gastrointestinal, hepatic or pulmonary disease
- •Patients with serious intercurrent illness, requiring hospitalization.
- •Other serious illnesses, e.g., serious infections requiring intravenous antibiotics or bleeding disorders.
- •Hypersensitivity to the active substances of study treatment or to any of the excipients (calcium, vitamin D)
- •Hereditary fructose intolerance
- •Women of childbearing potential: Refusal or inability to use highly effective means of contraception
- •For female patients: the patient is pregnant or lactating or planning to become pregnant within 5 months after the end of the treatment.
研究者
相似试验
进行中（未招募）
1 期
Effects of a treatment with Denosumab, applied together with either Nivolumab oder Pembrolizumab, in patients with skin cancer and bone metastasesEUCTR2016-001925-15-DEAlcedis GmbH20
已完成
不适用
Efficacy of the anti-RANKL human antibody (Denosumab) versus Bisphosphonate for the treatment of osteoporosis in patients with primary biliary cirrhosisOsteoporosis in biopsy-proven primary biliary cirrhosis patients pretreated with bisphosphonateJPRN-UMIN000012193Juntendo University School of Medicine60
已完成
不适用
Investigation of the effect of InterLeukin-1 receptor Antagonist on markers of inflammation in non-ST elevation acute coronary syndromeson-ST elevation acute coronary syndromesCirculatory SystemCoronary syndromesISRCTN89369318niversity of Sheffield (UK)186
已完成
2 期
To study the effect of Swarnaprashan in reducing the frequency of illness in children by improving the immunity and increasing the body strength.CTRI/2021/05/033713ational Institute of Ayurveda Jaipur Rajasthan30
进行中（未招募）
1 期
Evaluation of immunological response following a revaccination with a non-conjugated pneumococcal vaccine boosted or not by a conjugated pneumococcal vaccine in splenectomised patients (SPLENEVAC-2)Asplenic patients at risk for invasive pneumococcal diseasesMedDRA version: 20.0Level: PTClassification code 10041642Term: SplenectomySystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2018-003068-29-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)56